| Literature DB >> 33570492 |
Alex Macpherson1,2, Maisem Laabei2, Zainab Ahdash1, Melissa A Graewert3, James R Birtley1, Monika-Sarah Ed Schulze1, Susan Crennell2, Sarah A Robinson4, Ben Holmes1, Vladas Oleinikovas1, Per H Nilsson1,5,6, James Snowden1, Victoria Ellis1, Tom Eirik Mollnes6,7,8, Charlotte M Deane4, Dmitri Svergun3, Alastair Dg Lawson1, Jean Mh van den Elsen2,9.
Abstract
Bovines have evolved a subset of antibodies with ultra-long heavy chain complementarity determining regions that harbour cysteine-rich knob domains. To produce high-affinity peptides, we previously isolated autonomous 3-6 kDa knob domains from bovine antibodies. Here, we show that binding of four knob domain peptides elicits a range of effects on the clinically validated drug target complement C5. Allosteric mechanisms predominated, with one peptide selectively inhibiting C5 cleavage by the alternative pathway C5 convertase, revealing a targetable mechanistic difference between the classical and alternative pathway C5 convertases. Taking a hybrid biophysical approach, we present C5-knob domain co-crystal structures and, by solution methods, observed allosteric effects propagating >50 Å from the binding sites. This study expands the therapeutic scope of C5, presents new inhibitors, and introduces knob domains as new, low molecular weight antibody fragments, with therapeutic potential.Entities:
Keywords: bovine immunoglobulin; complement C5; human; immunology; inflammation; knob-domain peptides; molecular biophysics; structural biology
Mesh:
Substances:
Year: 2021 PMID: 33570492 PMCID: PMC7972453 DOI: 10.7554/eLife.63586
Source DB: PubMed Journal: Elife ISSN: 2050-084X Impact factor: 8.140